PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Garcia Campelo, M. R. [1 ]
Zhou, C. [2 ]
Ramalingam, S. S. [3 ]
Lin, H. M. [4 ]
Kim, T. M. [5 ]
Riely, G. J. [6 ]
Mekhail, T. [7 ]
Nguyen, D. [8 ]
Biber, J. [9 ]
Romero, H. [4 ]
Goodman, E. [4 ]
Popat, S. [10 ,11 ]
Janne, P. A. [12 ]
机构：
[1] Complejo Hosp Univ A Coruna, La Coruna, Spain
[2] Shanghai Pulm Hosp, Shanghai, Peoples R China
[3] Emory Univ, Atlanta, GA USA
[4] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
[7] AdventHealth, Orlando, FL USA
[8] City Hope Natl Med Ctr, Los Angeles, CA USA
[9] Xcenda LLC, Carrollton, TX USA
[10] Royal Marsden Hosp, London, England
[11] Inst Canc Res, London, England
[12] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; exon20; insertion; patient-reported outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-17
引用
收藏
页码：S487 / S488
页数：2
相关论文
共 50 条
  • [41] Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer
    Xie, Yuhao
    Lu, Qisi
    Wang, Jing-Quan
    Bo, Letao
    Ashby, Charles R., Jr.
    Chen, Zhe-Sheng
    [J]. DRUGS OF TODAY, 2022, 58 (08) : 389 - 398
  • [42] Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Wang, Mengzhao
    Yang, James Chih-Hsin
    Mitchell, Paul L.
    Fang, Jian
    Camidge, D. Ross
    Nian, Weiqi
    Chiu, Chao-Hua
    Zhou, Jianying
    Zhao, Yanqiu
    Su, Wu-Chou
    Yang, Tsung-Ying
    Zhu, Viola W.
    Millward, Michael
    Fan, Yun
    Huang, Wen-Tsung
    Cheng, Ying
    Jiang, Liyan
    Brungs, Daniel
    Bazhenova, Lyudmila
    Lee, Chee Khoon
    Gao, Bo
    Xu, Yan
    Hsu, Wei-Hsun
    Zheng, Li
    Janne, Pasi A.
    [J]. CANCER DISCOVERY, 2022, 12 (07) : 1676 - 1689
  • [43] A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
    Yoh, Kiyotaka
    Azuma, Koichi
    Hayashi, Hidetoshi
    Nishio, Makoto
    Chikamori, Kenichi
    Ichihara, Eiki
    Watanabe, Yasutaka
    Asato, Takayuki
    Kitagawa, Tadayuki
    Fram, Robert J.
    Ohe, Yuichiro
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [44] EGFR-mutated disease: early combinations and new approaches in exon 20 insertion-positive lung cancer
    不详
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (SUPPL 3) : S75 - S78
  • [45] Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report
    Bin-Bin Shan
    Yuan Li
    Chang Zhao
    Xiao-Qin An
    Quan-Mao Zhang
    [J]. World Journal of Clinical Cases, 2022, (06) : 1883 - 1888
  • [46] Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma A case report
    Inagaki, Yuji
    Tamiya, Akihiro
    Matsuda, Yoshinobu
    Azuma, Kouji
    Adachi, Yuichi
    Enomoto, Takatoshi
    Kouno, Shunichi
    Taniguchi, Yoshihiko
    Saijo, Nobuhiko
    Okishio, Kyoichi
    Atagi, Shinji
    [J]. MEDICINE, 2020, 99 (42)
  • [47] Mobocertinib in non-small cell lung cancer
    Liu, Shengwu
    Lowder, Kristen E.
    [J]. DRUGS OF TODAY, 2022, 58 (11) : 523 - 530
  • [48] Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation
    Lam, N. S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S510 - S510
  • [49] Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'
    Inagaki, Yuji
    Tamiya, Akihiro
    [J]. LUNG CANCER, 2020, 148 : 179 - 180
  • [50] Identification of Mechanisms of Acquired Resistance to Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
    Elamin, Y.
    Robichaux, J.
    Carter, B.
    Altan, M.
    Gibbons, D.
    Fossella, F.
    Simon, G.
    Lam, V.
    Blumenschein, G., Jr.
    Tsao, A.
    Kurie, J.
    Mott, F.
    Negrao, M.
    Hu, L.
    He, J.
    Nilsson, M.
    Roeck, B.
    Yang, Z.
    Papadimitrakopoulou, V.
    Heymach, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S282 - S283
12345